JP2013526840A - 組み換えブチリルコリンエステラーゼおよびその切断型 - Google Patents

組み換えブチリルコリンエステラーゼおよびその切断型 Download PDF

Info

Publication number
JP2013526840A
JP2013526840A JP2012545932A JP2012545932A JP2013526840A JP 2013526840 A JP2013526840 A JP 2013526840A JP 2012545932 A JP2012545932 A JP 2012545932A JP 2012545932 A JP2012545932 A JP 2012545932A JP 2013526840 A JP2013526840 A JP 2013526840A
Authority
JP
Japan
Prior art keywords
nucleic acid
bche
isolated nucleic
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012545932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526840A5 (enExample
Inventor
イム，カルバン
ダンソー，スティーブン
ハウスクネヒト，エドワード
Original Assignee
ファーマシーネ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマシーネ，インコーポレイテッド filed Critical ファーマシーネ，インコーポレイテッド
Publication of JP2013526840A publication Critical patent/JP2013526840A/ja
Publication of JP2013526840A5 publication Critical patent/JP2013526840A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012545932A 2009-12-21 2010-12-21 組み換えブチリルコリンエステラーゼおよびその切断型 Ceased JP2013526840A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28444409P 2009-12-21 2009-12-21
US61/284,444 2009-12-21
PCT/US2010/003225 WO2011084145A2 (en) 2009-12-21 2010-12-21 Recombinant butyrylcholinesterases and truncates thereof

Publications (2)

Publication Number Publication Date
JP2013526840A true JP2013526840A (ja) 2013-06-27
JP2013526840A5 JP2013526840A5 (enExample) 2014-02-13

Family

ID=44306009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012545932A Ceased JP2013526840A (ja) 2009-12-21 2010-12-21 組み換えブチリルコリンエステラーゼおよびその切断型

Country Status (6)

Country Link
US (2) US8729245B2 (enExample)
EP (1) EP2516664B1 (enExample)
JP (1) JP2013526840A (enExample)
AU (1) AU2010340358B2 (enExample)
CA (1) CA2784861A1 (enExample)
WO (1) WO2011084145A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138390A (ko) * 2015-04-24 2017-12-15 훼링 비.브이. 고나도트로핀 생산 방법
KR20180077275A (ko) * 2015-11-05 2018-07-06 뱀부 테라퓨틱스 인코포레이티드 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터
JP2023540599A (ja) * 2020-09-07 2023-09-25 フンダシオン インスティチュート デ インベスティガシオン サニタリア フンダシオン ヒメネス ディアス Ｃｘｃｒ４及びｉｌ－１０を共発現する間葉系幹細胞並びにその使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084145A2 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
US9688970B2 (en) 2013-10-01 2017-06-27 Kentucky Bioprocessing, Inc. Plant-based recombinant butyrylcholinesterase production methods
CN108486114A (zh) * 2018-04-18 2018-09-04 西南大学 实现两个基因等量表达的基因元件及表达载体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024567A1 (en) * 2007-08-20 2009-02-26 Glaxo Group Limited Production method
WO2009046464A1 (en) * 2007-10-05 2009-04-09 Merial Limited Articular cartilage gene therapy with recombinant vector encoding bmp-7
JP2009183295A (ja) * 2001-10-11 2009-08-20 Merck & Co Inc Ｃ型肝炎ウイルスワクチン

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US5215909A (en) 1986-06-18 1993-06-01 Yeda Research & Development Co., Ltd. Human cholinesterase genes
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
IL89703A (en) 1989-03-21 2001-10-31 Yissum Res Dev Co Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof
US5227301A (en) 1989-11-03 1993-07-13 The 501 Institution For The Advancement Of Learning (Mcgill University) Immortalized bovine mannary epithelial cell line
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5831141A (en) 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
IL101600A (en) 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US6110742A (en) 1992-04-15 2000-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides targeted to AChE
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5932780A (en) 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
US6025183A (en) 1994-02-28 2000-02-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transgenic animal assay system for anti-cholinesterase substances
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US5807671A (en) 1995-01-09 1998-09-15 Yissum Research Development Company Of Hebrew University Of Jerusalem Method of screening for genetic predisposition to anticholinesterase therapy
US5780009A (en) 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
IL115873A0 (en) 1995-11-03 1996-01-31 Peri Dev Applic 1985 Ltd Transgenic protein production
US6326139B1 (en) 1996-01-11 2001-12-04 Yissum Research Development Company Of Hebrew University Of Jerusalem Method of screening for genetic predisposition to anticholinesterase therapy
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US20020184655A1 (en) 1997-12-01 2002-12-05 Henryk Lubon Methods for the degradation and detoxification of organic material using urine produced by transgenic animals and related transgenic animals and proteins
US7157615B2 (en) 1998-03-17 2007-01-02 Nexia Biotechnologies, Inc. Production of biofilaments in transgenic animals
ATE253126T1 (de) 1998-08-25 2003-11-15 Univ Washington Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen
JP2002525047A (ja) 1998-09-16 2002-08-13 ネクシア バイオテクノロジーズ， インコーポレイテッド 尿における組換え蛋白質の産生
US6580017B1 (en) 1998-11-02 2003-06-17 Genzyme Transgenics Corporation Methods of reconstructed goat embryo transfer
WO2000029608A1 (en) 1998-11-13 2000-05-25 New York University Transgenic animals as urinary bioreactors for the production of protein in the urine, recombinant dna construct for kidney-specific expression, and method of using same
AU2492400A (en) 1999-01-06 2000-07-24 Atlantic Biopharmaceuticals, Inc. Expression of secreted human alpha-fetoprotein in transgenic animals
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
EP1175453B1 (en) 1999-04-26 2003-10-29 U.S. Army Medical Research and Materiel Command Differentially acting op detoxifying sponges
IL131707A0 (en) 1999-05-31 2001-03-19 Yissum Res Dev Co Acetylcholinesterase-derived peptides and uses thereof
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
IL142875A (en) 2001-04-30 2009-08-03 Avigdor Shafferman PEG-linked cholinesterases for the detoxification of circulating organophosphorus
MY137181A (en) 2001-05-21 2009-01-30 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US7078507B2 (en) * 2001-11-09 2006-07-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Synthetic genes for malarial proteins and methods of use
AU2002353374A1 (en) 2001-12-21 2003-07-09 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
EP1581253A4 (en) * 2002-12-04 2007-02-14 Applied Molecular Evolution BUTYRYLCHOLINESTERASE VARIANTS MODIFYING THE ACTIVITY OF CHEMOTHERAPEUTIC AGENTS
WO2005035788A2 (en) 2003-10-10 2005-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and kit for assessing anxiety or disposition thereto in a subject
EP2053409A1 (en) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Specific markers for metabolic syndrome
WO2005066337A2 (en) 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
US20060194301A1 (en) 2004-10-09 2006-08-31 Doctor Bhupendra P Large-scale production of human serum butyrylcholinesterase as a bioscavenger
US9062321B2 (en) 2004-12-01 2015-06-23 Arizona Board Of Regents On Behalf Of Arizona State University Codon-optimized polynucleotides encoding human butyrylcholinesterase and plant expression systems therof
US20090249503A1 (en) 2004-12-06 2009-10-01 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
EP2423315B1 (en) 2006-06-29 2015-01-07 DSM IP Assets B.V. A method for achieving improved polypeptide expression
EP2049661A4 (en) 2006-08-04 2012-07-04 Pharmathene Inc RECOMBINANT BUTYRYLCHOLINESTERASE WITH LONG HALF-LIFE
WO2011084145A2 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009183295A (ja) * 2001-10-11 2009-08-20 Merck & Co Inc Ｃ型肝炎ウイルスワクチン
WO2009024567A1 (en) * 2007-08-20 2009-02-26 Glaxo Group Limited Production method
WO2009046464A1 (en) * 2007-10-05 2009-04-09 Merial Limited Articular cartilage gene therapy with recombinant vector encoding bmp-7

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6015000169; Ｔａｙｌｏｒ，Ｐ．: '"Ａｃｃｅｓｓｉｏｎ：Ｍ９９４９２［ｇｉ：１９１５７９］，Ｄｅｆｉｎｉｔｉｏｎ：Ｍｏｕｓｅ　ｂｕｔｙｒｙｌｃｈｏｌｉｎｅｓｔｅｒａｓｅ　ｍＲＮＡ，　ｃｏｍｐｌｅｔｅ　ｃｄｓ．"' ＮＣＢＩ　Ｅｎｔｒｅｚ　Ｎｕｃｌｅｏｔｉｄｅ［ｏｎｌｉｎｅ］；３０-ＮＯＶ-２００９　ｕｐｌｏａｄｅｄ，ＮＣＢＩ *
JPN6015000170; ＭｃＴｉｅｒｎａｎ，Ｃ．ｅｔ　ａｌ．: '"Ａｃｃｅｓｓｉｏｎ：Ｍ１６５４１［ｇｉ：１２８０２０４］，Ｄｅｆｉｎｉｔｉｏｎ：Ｈｕｍａｎ　ｂｕｔｙｒｙｌｃｈｏｌｉｎｅｓｔｅｒａｓｅ，　ｍＲＮＡ，　ｃｏｍｐｌｅｔｅ　ｃｄｓ．"' ＮＣＢＩ　Ｅｎｔｒｅｚ　Ｎｕｃｌｅｏｔｉｄｅ［ｏｎｌｉｎｅ］；１０-ＪＵＬ-２００９　ｕｐｌｏａｄｅｄ，ＮＣＢＩ *
JPN6015000173; Ｅｕｒ．Ｊ．Ｂｉｏｃｈｅｍ．，２００２，２６９（２），ｐ．６３０-７ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138390A (ko) * 2015-04-24 2017-12-15 훼링 비.브이. 고나도트로핀 생산 방법
JP2018512885A (ja) * 2015-04-24 2018-05-24 フェリング ベスローテン フェンノートシャップ ゴナドトロピンの製造方法
KR102658666B1 (ko) * 2015-04-24 2024-04-17 훼링 비.브이. 고나도트로핀 생산 방법
KR20180077275A (ko) * 2015-11-05 2018-07-06 뱀부 테라퓨틱스 인코포레이티드 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터
JP2018531609A (ja) * 2015-11-05 2018-11-01 バンブー セラペウティクス インク 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
KR102200642B1 (ko) 2015-11-05 2021-01-12 뱀부 테라퓨틱스 인코포레이티드 유전자 치료를 위한 변형된 프리드라이히 운동실조증 유전자 및 벡터
JP2021019591A (ja) * 2015-11-05 2021-02-18 バンブー セラペウティクス インク 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
JP2023540599A (ja) * 2020-09-07 2023-09-25 フンダシオン インスティチュート デ インベスティガシオン サニタリア フンダシオン ヒメネス ディアス Ｃｘｃｒ４及びｉｌ－１０を共発現する間葉系幹細胞並びにその使用

Also Published As

Publication number Publication date
US8952143B2 (en) 2015-02-10
US20120252094A1 (en) 2012-10-04
US20140220658A1 (en) 2014-08-07
WO2011084145A3 (en) 2013-05-30
EP2516664B1 (en) 2015-07-22
US8729245B2 (en) 2014-05-20
EP2516664A4 (en) 2013-11-13
AU2010340358A1 (en) 2012-07-19
EP2516664A1 (en) 2012-10-31
AU2010340358B2 (en) 2014-07-24
WO2011084145A2 (en) 2011-07-14
CA2784861A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
JP7662157B2 (ja) ヒト化細胞系
McBlane et al. Cleavage at a V (D) J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps
KR102474010B1 (ko) 유전적 병태를 치료하기 위한 방법 및 조성물
EP2449135B1 (en) Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
JP2025032080A (ja) 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法
EP3262168B1 (en) Host cell protein modification
US8952143B2 (en) Recombinant butyrylcholinesterases and truncates thereof
US20240279630A1 (en) Isolated cas13 protein and use thereof
JP2022097653A (ja) ヒトα－ガラクトシダーゼバリアント
KR20230005865A (ko) 전위-기반 요법
JPH09509851A (ja) ヒトホスホジエステラーゼ型ｉｖｃ、並びにその生産および使用
KR20190088483A (ko) 신규 엔도-β-N-아세틸글루코사미니다아제
TW202444921A (zh) 用於靶向lpa之組合物及方法
Ceylan et al. Cloning, expression, and characterization of human brain acetylcholinesterase in Escherichia coli using a SUMO fusion tag
AU2011298451B2 (en) Use of a HSPC117 molecule as RNA ligase
US20210108188A1 (en) Non-covalent systems and methods for dna editing
CN115279419A (zh) 用于基因组工程的组合物和方法
KR101906442B1 (ko) 피스코미트렐라 파텐스에서 프롤릴-4-히드록실라아제의 변형된 발현
RU2820830C2 (ru) Линия клеток, содержащая новый маркер отбора, и ее применение для продуцирования белков
RU2732795C1 (ru) Рекомбинантный слитый белок
US20250195690A1 (en) Gene therapy DNA vector based on gene therapy DNA vector GDTT1.8NAS12 carrying HFE therapeutic gene for enhanced expression of the therapeutic gene, method of its production and use, Escherichia coli strain JM110-NAS/GDTT1.8NAS12-HFE carrying the gene therapy DNA vector, method of its production, method of the gene therapy DNA vector production on an industrial scale
PL240561B1 (pl) Wektory DNA zdolne do transformacji i integracji z chromosomem Leishmania tarentolae zawierające gen kodujący butyrylocholinoesterazę BChE
US20230323335A1 (en) Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
WO2025213929A1 (zh) 一种工程化胞嘧啶脱氨酶及其制备方法和用途
HK40092826A (en) Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150615

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151020

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20160223